Lung cancer drug could improve survival rates for bladder cancer patients undergoing chemotherapy
Researchers found that adding nintedanib - a targeted cancer growth inhibitor currently used to treat non-small cell lung cancer - to chemotherapy, could significantly improve overall survival rate for bladder cancer patients.